Apogee Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APGE research report →
About the company
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD.
- CEO
- Michael Thomas Henderson
- IPO
- 2023
- Employees
- 196
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $8.20B
- P/E
- -33.72
- P/S
- 0.00
- P/B
- 7.37
- EV/EBITDA
- -28.44
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.64%
- ROIC
- -24.15%
- Revenue
- $0 · 0.00%
- Net Income
- $-255,843,000 · -40.46%
- EPS
- $-4.22 · -27.88%
- Op Income
- $-285,595,000
- FCF YoY
- -34.97%
- 52W High
- $133.85
- 52W Low
- $34.34
- 50D MA
- $92.61
- 200D MA
- $73.66
- Beta
- 0.62
- Avg Volume
- 2.44M
Get TickerSpark's AI analysis on APGE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Dambkowski Carl | other | 4,125 |
| Jul 1, 26 | Dambkowski Carl | sell | 5,500 |
| Jul 1, 26 | Dambkowski Carl | other | 4,125 |
| Jun 22, 26 | Dambkowski Carl | sell | 26,400 |
| Jun 22, 26 | HENDERSON MICHAEL THOMAS | sell | 80,000 |
| Jun 10, 26 | HENDERSON MICHAEL THOMAS | sell | 6,770 |
| Jun 10, 26 | HENDERSON MICHAEL THOMAS | sell | 7,654 |
| Jun 10, 26 | HENDERSON MICHAEL THOMAS | sell | 1,080 |
| Jun 10, 26 | HENDERSON MICHAEL THOMAS | sell | 1,577 |
| Jun 10, 26 | HENDERSON MICHAEL THOMAS | sell | 2,305 |
Our APGE coverage
Recent articles, reports, and earnings notes.
No research on APGE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APGE report →Similar companies
Peers in the same neighborhood.